5. Conclusion
Our meta-analysis addressed the problems of previous meta-analyses and also included more studies. The OS, DFS, and DSS did not differ significantly between early stage OSCC patients without clinical neck metastases undergoing SNB and END. SNB, which has no life-threatening side effects, is preferable to END for patients with early stage clinically node-negative OSCC.